Patheon to invest $45 million, expanding capabilities to support continued growth
Investments in commercial and development spray drying, and flexible manufacturing solutions.
Patheon expects to invest approximately $45 million at key sites across its global network to meet growing customer demand for expanded service capabilities.
“As outsourcing of pharma development and manufacturing services continues to grow, our customers will need even more advanced technologies and customized solutions to meet their business needs,” said Michel Lagarde, president of Patheon. “With the increasing marketplace pressures, pharma companies are looking to build more reliable, flexible and cost-efficient supply chains. With our focus on people, process and capabilities, Patheon is uniquely positioned to partner with pharma companies to achieve their objectives – cost effectively while delivering the highest quality.”
Patheon is investing in the following key areas:
Commercial & Development Spray DryingThe company’s recently acquired site located in Florence, South Carolina, will be adding commercial spray drying capabilities, complementing the existing development capabilities available at the company’s low-solubility center of excellence in Bend, Oregon. The 15,000-sq.-ft. dedicated suite will contain two spray dryers delivering development and commercial scale spray-dried dispersion (SDD) services. The suite is expected to be online in 2019. Spray Drying is a process that creates amorphous solid dispersions and is a key technology utilized to enhance the solubility of poorly soluble drugs.
At the Bend, Oregon site the company plans to expand existing development SDD capabilities with a new cGMP analytical lab, manufacturing suite and additional development scale spray drying. Together, the expertise and capabilities at the Florence and Bend locations provide clients with an end-to-end solution for products with solubility challenges, from development to commercialization, to successfully bring products to market.
Flexible Manufacturing SolutionsPatheon has invested in a new commercial sterile product manufacturing facility in its Monza, Italy site. The facility will house three, 40 m2 lyophilizers with associated eight-headed integrated filling equipment for both lyo and liquid formulations for small and large molecules in a range of vial specifications. The equipment will have full CIP/SIP systems, auto loading for the lyophilizers contained in full RABs systems to ensure the highest level of sterility assurance.
Patheon also plans to expand its sterile product Pharmaceutical Development Services (PDS) at the Monza facility. The sterile suite will contain two 7 m2 lyophilizers and associated sterile vial filling line and analytical laboratory. This new facility will serve the company’s clients seeking to develop both small and large molecule injectable products (liquid and lyo formulations) and will be operational in mid-2019. All of Patheon’s PDS sterile suites are co-located within facilities with commercial scale capabilities to ease with the transition from clinical to commercialization.
Patheon will also expand its packaging and serialization capabilities at its Greenville, NC site. The company has built a new filling and packaging suite and upgraded another of its packaging lines with new technology to improve efficiency and reduce change-over time. The newly constructed 4,800-sq.-ft suite will come online this fall and features a filling and packaging line equipped with an Optel serialization system. The state-of-the-art system includes cameras, pharma proof stations, line master, and bottle and bundle tracker equipment.
These investments will help clients realize greater efficiency and accelerate the delivery of products to market.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance